eubiologics

Company

Global biopharmaceutical company providing safety, health and future

Company History

EuBiologics Co., Ltd. is growing by leaps and bounds and contributing to global public health through innovative products and technology.

2020

  • 10Established a joint venture company, EUPOP Life Sciences, with POP Biotechnologies, Inc. of USA

2019

  • 12Received 20 Million Dollar Export Tower Award
  • 04Completed construction of Plant 2 (V Plant) in Chuncheon, Korea

2018

  • 12Received 10 Million Dollar Export Tower Award
  • 03Started construction of Plant 2 (V Plant) in Chuncheon, Korea

2017

  • 12Entered into the EcML Technology Transfer Agreement with KIST
  • 08Received WHO Prequalification certificate for OCV (Euvichol-Plus)
  • 01Listed on KOSDAQ

2016

  • 10Started exporting OCV (Euvichol®) (including one million doses to Haiti, etc.)
  • 06Entered into the Long-Term Agreement with UNICEF for OCV (Euvichol®) supply

2015

  • 12Received WHO PQ certification for OCV (Euvichol®)
  • 01Received export license for OCV (Euvichol®) from KMFDS

2014

  • 09Expanded production facilities for Active Pharmaceutical Ingredient for Euvichol® (w.v.600L)
  • 08Completed Phase 3 Clinical Trial for OCV (Euvichol®) in Philippines
  • 08Received investment from Global Health Investment Fund (GHIF) of the Bill and Melinda Gates Foundation

2013

  • 12Received IND approval for Phase 3 Clinical Trial of OCV (Euvichol®) in Philippines

2012

  • 07IND approved for Phase 1 Clinical Trial of OCV (Euvichol®) in Korea
  • 06Conducted Government Assignment for next generation typhoid vaccine (Small and Medium Business Administration)
  • 03Merged with EuBiopharm Co., Ltd.
  • 02Received the Venture Company Certificate

2010

  • 12Performed the Technology Transfer and Feasibility study
  • 09Entered into the Technology Transfer Agreement for oral cholera vaccine (OCV) with International Vaccine Institute (IVI)
  • 03EuBiologics Co., Ltd. founded